Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | completed | Phase 1 / Phase 2 | 40 | Baylor College of MedicineOTHER | 1 |
| Jan 18, 2020 |
| clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00651937 | Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00925782 | PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation | completed | Phase 2 | 24 | Acrotech Biopharma Inc.INDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00450814 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 48 | Mayo ClinicOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00581919 | Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma | completed | Phase 2 | 32 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02410694 | Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 90 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Dec 13, 2019 | clinicaltrials |
| NCT02057640 | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Jason ValentOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
| NCT00866138 | Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 | completed | Phase 2 | 24 | AB ScienceINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT01352286 | Redirected Auto T Cells for Advanced Myeloma | completed | Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
| NCT02290431 | Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT00445692 | Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | completed | Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT00044018 | CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 102 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00065351 | Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 222 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT01142232 | Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | completed | Phase 1 / Phase 2 | 60 | Attaya SuvannasankhaOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00657488 | Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 400 | CelgeneINDUSTRY | 2 | Oct 18, 2019 | clinicaltrials |
| NCT01602224 | A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | completed | Phase 2 | 220 | Eli Lilly and CompanyINDUSTRY | 15 | Oct 8, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00948922 | Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | completed | Phase 2 | 124 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01955434 | SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | Mayo ClinicOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT00997386 | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States(ALBUM) | completed | Phase 2 | 16 | University of ArizonaOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02944565 | Daratumumab in Treating Patients With Multiple Myeloma | completed | Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT01447914 | Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01001442 | Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02880228 | Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant | completed | Phase 2 | 11 | Mayo ClinicOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01638936 | BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 148 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 17, 2019 | clinicaltrials |
| NCT02159365 | Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | completed | Phase 2 | 84 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02188537 | Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | completed | Phase 2 | 34 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02176213 | Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 35 | Ajai ChariOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00153920 | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | completed | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01008462 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01159574 | Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | completed | Phase 2 | 121 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT00916058 | Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 57 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01517724 | Bortezomib Consolidation Trial(BCT) | completed | Phase 2 | 40 | University College, LondonOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01521611 | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | completed | Phase 1 / Phase 2 | 62 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00439465 | Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma | completed | Phase 2 | 23 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00807599 | Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | completed | Phase 2 | 67 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01481194 | ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma(ACVDL) | completed | Phase 2 | 35 | Vejle HospitalOTHER | 1 | Mar 1, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2020source: clinicaltrials